Breaking News, Collaborations & Alliances

Novartis, Regenerex in Global Licensing and Research Alliance

Will use FCRx platform kidney transplantation and metabolic storage disorders

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Novartis has entered into an exclusive global licensing and research collaboration with Regenerex to use the company’s novel Facilitating Cell Therapy (FCRx) platform, which has been investigated in kidney transplantation to induce stable immunological tolerance, eliminating the need for lifelong immunosuppression. Regenerex’s platform will also be investigated in serious genetic deficiencies such as inherited metabolic storage disorders and hemoglobinopathies.   FCRx expands Novarti...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters